EXCERPT:
Lilly’s acquisition of Orna Therapeutics brings circular RNA and LNP delivery technology into one of pharma’s largest genetic medicine pipelines. The deal signals serious commercial interest in circRNA as the next mRNA evolution.
CONTENT:
On February 9, 2026, Eli Lilly entered into a definitive agreement to acquire Orna Therapeutics for up to $2.4 billion in cash. The deal centers on Orna’s circular RNA platform and its lipid nanoparticle delivery capabilities.
Circular RNA differs from standard mRNA in one key way: it has no free ends, making it resistant to the exonucleases that degrade linear mRNA. That structural advantage translates to longer expression duration without the need for chemical modifications — a significant potential benefit for repeat-dosing indications and applications where sustained protein expression matters.
For those working in LNP formulation and delivery, this deal is worth watching closely. The LNP platforms being acquired aren’t just vehicles — they’re increasingly the differentiating asset. As circRNA moves from academic novelty to clinical reality, the demand for specialized analytical and formulation support will follow.